Contrast-Enhanced, High-Resolution, Susceptibility-Weighted Magnetic Resonance Imaging of the Brain

Abstract

Only a standard dose (0.1 mmol/kg) of gadobenate dimeglumine is required to achieve the optimum susceptibility effect and image quality at 3 T, together with a reduced scan time. This result can be attributed to the higher relaxivity of gadobenate dimeglumine, compared with conventional gadolinium chelates.

High-Resolution Contrast-Enhanced, Susceptibility-Weighted MR Imaging at 3T in Patients with Brain Tumors: Correlation with Positron-Emission Tomography and Histopathologic Findings

“…This can be explained by the fact that, before patient examinations, a volunteer study was performed to determine the optimal dose of the contrast agent with known high relaxivity so as to achieve the best compromise between image quality and scan time for the clinical application of 3T HR-CE-SW-MR imaging. 12 In contrast to a previously conducted study by Barth et al, 1 which used a double dose of gadopentate-dimeglumine as a contrast agent, only a standard dose of gadobenate dimeglumine (MultiHance) was required to achieve the optimal SusE and image quality at 3T, together with a reduced scan time. 12 In 6 selected patients, a direct side-to-side correlation of histopathologic specimens from the lesions and intralesional MR-SusE was performed.…”

“…12 In contrast to a previously conducted study by Barth et al, 1 which used a double dose of gadopentate-dimeglumine as a contrast agent, only a standard dose of gadobenate dimeglumine (MultiHance) was required to achieve the optimal SusE and image quality at 3T, together with a reduced scan time. 12 In 6 selected patients, a direct side-to-side correlation of histopathologic specimens from the lesions and intralesional MR-SusE was performed. Regions with high frequency of intralesional SusE corresponded with conglomerates of vascular proliferations.…”

“…12 A standard dose of gadobenate-dimeglumine (0.1 mmol or 0.2 mL/kg of body weight) proved optimal to achieve an equivalent SusE and image quality, together with a considerable reduction in scan time compared with unenhanced 3T HR-SW-MR imaging. 12 All of the patients in our study received the previously determined dose of 0.1 mmol/L (0.2 mL/kg of body weight) of IV gadobenate-dimeglumine administered as a bolus. The data acquisition for each examination was started after a standard delay (10 minutes) and completed within 1 hour after contrast agent application.…”

“…12 The contrast agent used was gadobenate-dimeglumine (MultiHance, Bracco Imaging, Milan, Italy) with a proton magnetic relaxivity twice that of other available standard paramagnetic contrast agents. 12 A standard dose of gadobenate-dimeglumine (0.1 mmol or 0.2 mL/kg of body weight) proved optimal to achieve an equivalent SusE and image quality, together with a considerable reduction in scan time compared with unenhanced 3T HR-SW-MR imaging. 12 All of the patients in our study received the previously determined dose of 0.1 mmol/L (0.2 mL/kg of body weight) of IV gadobenate-dimeglumine administered as a bolus.…”

“…11 Therefore, compared with 1.5T, high-field (3T) HR contrast-enhanced (CE)-SW-MR imaging allows for optimal susceptibility effects (SusE) at shorter measurement times. 1,4,12 Clinical applications of 3T HR-CE-SW-MR imaging include improved visualization of cerebral vascular malformations, such as cavernous angiomas, arteriovenous malformations, detection of developmental venous anomalies, cerebral venous thrombosis, and intracranial hemorrhage. 12,13 3T HR-CE-SW-MR imaging of highly vascularized tumors also shows complex and variable venous patterns in various types of tumors and in different parts of the lesions, 1 which might be because of the increased blood supply and particular vascular patterns associated with fast-growing tumors.…”